{"id":"W1969175190","doi":"10.1073/pnas.1220763110","title":"Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; University of Alberta; Università degli Studi di Milano; European Commission; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Israel Cancer Research Fund","keywords":"Cetuximab; Epidermal growth factor receptor; Panitumumab; Monoclonal antibody; Triple-negative breast cancer; Cancer research; Antibody; EGFR inhibitors; Growth inhibition; Epidermal growth factor; Receptor; Chemistry; Breast cancer; Cell growth; Biology; Medicine; Cancer; Immunology; Internal medicine; Biochemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034564,0.0006155956,0.0004150601,0.0003239346,0.0001539425,0.0002747311,0.0003108377,0.0002715499,0.0007970686],"category_scores_gemma":[0.00009996654,0.0001441614,0.0003178189,0.000122971,0.0001491271,0.0001964102,0.0001535578,0.0006118865,0.000184973],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003137615,"about_ca_system_score_gemma":0.0003377491,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009264179,"about_ca_topic_score_gemma":0.002904683,"domain_scores_codex":[0.9998097,0.00004266362,0.00001694115,0.00002761854,0.00006052976,0.00004256105],"domain_scores_gemma":[0.9999272,0.00001589811,0.00001618401,0.00001003895,0.000008437234,0.00002221584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001708027,0.0001462241,0.00008747893,0.00004777814,0.00001389014,0.00003894595,0.00001300898,0.0001594554,0.9971163,0.000161943,0.00009644751,0.001947674],"study_design_scores_gemma":[0.00002176927,0.000678733,0.0003954459,0.000003365889,0.00002279034,0.0001347005,0.000004925325,0.0006156432,0.9968291,0.00002142896,0.001269193,0.000002924001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981369,0.003182585,0.01090835,0.0002043239,0.00009017879,0.0002514341,0.0003192536,0.0001986606,0.003476205],"genre_scores_gemma":[0.984314,0.00201728,0.01007446,0.00008791565,0.00002223922,0.0001399511,0.0003581272,0.00003336354,0.002952606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009264179,"threshold_uncertainty_score":0.002666414,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.073597400590453,"score_gpt":0.3849994061081312,"score_spread":0.3114020055176782,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}